Drug Trial Radar · NCT07464132
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Feb 17, 2027
Study completion Jun 17, 2027
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
Conditions
- Tumor
- Cardiovascular Diseases
- Pulmonary Fibrosis
- Rheumatic Immune Diseases Involving Large Blood Vessels
- Hypertrophic Cardiomyopathy (HCM)
- Other Hypoxic and Fibroblast Activated Diseases
Interventions
Injection of 68Ga-NI-FAPIDrug
Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight
Primary outcomes
What the sponsor says the trial is designed to measure.
- Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04Time frame: Within 30-120 minutes after intravenous injection of imaging agent
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.